Literature DB >> 9886238

Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors.

H van de Waterbeemd1, G Camenisch, G Folkers, J R Chretien, O A Raevsky.   

Abstract

The influence of physicochemical properties, including lipophilicity, H-bonding capacity and molecular size and shape descriptors on brain uptake has been investigated using a selection of marketed CNS and CNS-inactive drugs. It is demonstrated that the polar surface area of a drug can be used as a suitable descriptor for the drugs' H-bonding potential. A combination of a H-bonding and a molecular size descriptor, i.e., the major components of lipophilicity and permeability, avoiding knowledge of distribution coefficients, is proposed to estimate brain penetration potential of new drug candidates. Previously reported experimental surface activity data appear to be strongly correlated to molecular size of the drug compounds. Present analysis offers a modern basis for property-based design and targeting of CNS drugs.

Mesh:

Year:  1998        PMID: 9886238     DOI: 10.3109/10611869808997889

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  95 in total

Review 1.  Lipophilicity in PK design: methyl, ethyl, futile.

Authors:  H van de Waterbeemd; D A Smith; B C Jones
Journal:  J Comput Aided Mol Des       Date:  2001-03       Impact factor: 3.686

2.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

3.  Computational models to predict blood-brain barrier permeation and CNS activity.

Authors:  Govindan Subramanian; Douglas B Kitchen
Journal:  J Comput Aided Mol Des       Date:  2003-10       Impact factor: 3.686

4.  In silico strategies for the selection of chelating compounds with potential application in metal-promoted neurodegenerative diseases.

Authors:  Cristina Rodríguez-Rodríguez; Albert Rimola; Jorge Alí-Torres; Mariona Sodupe; Pilar González-Duarte
Journal:  J Comput Aided Mol Des       Date:  2011-01       Impact factor: 3.686

5.  Chimeric p53 as an alternative therapy for hypoxic tumors.

Authors:  Jun-Ho Lee; Hua Lu
Journal:  Cancer Biol Ther       Date:  2011-01-01       Impact factor: 4.742

Review 6.  How to measure drug transport across the blood-brain barrier.

Authors:  Ulrich Bickel
Journal:  NeuroRx       Date:  2005-01

Review 7.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

8.  Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.

Authors:  Dilip K Tosh; Harsha Rao; Amelia Bitant; Veronica Salmaso; Philip Mannes; David I Lieberman; Kelli L Vaughan; Julie A Mattison; Amy C Rothwell; John A Auchampach; Antonella Ciancetta; Naili Liu; Zhenzhong Cui; Zhan-Guo Gao; Marc L Reitman; Oksana Gavrilova; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2019-01-03       Impact factor: 7.446

9.  Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses.

Authors:  Weiping Peng; Daniel C Peltier; Martha J Larsen; Paul D Kirchhoff; Scott D Larsen; Richard R Neubig; David J Miller
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

10.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.